Vital KSK HoldingsTSE:3151 -0.85%68 EBITDA Margin % is 4.38% as of Mar. 2026, which is 122% above its 10-year median of 1.97. GuruFocus rates TSE:3151 with a GF Score™ of 68/100 and a GF Value™ of 円1,322.65 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 119 Medical Distribution companies, Vital KSK Holdings ranks worse than 69.75% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Vital KSK Holdings's EBITDA for the
three
months ended in Mar. 2026 was 円6,394 Mil. Vital KSK Holdings's Revenue for the
three
months ended in Mar. 2026 was 円145,943 Mil. Therefore, Vital KSK Holdings's EBITDA margin for the quarter that ended in Mar. 2026 was 4.38%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vital KSK Holdings EBITDA Margin % Related Terms
Vital KSK Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vital KSK Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3151 vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Vital KSK Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vital KSK Holdings EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Vital KSK Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vital KSK Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vital KSK Holdings (TSE:3151) has a EBITDA Margin % of 4.38% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vital KSK Holdings and its competitors. This is 122% above median its historical median of 1.97. Over the past decade, Vital KSK Holdings' EBITDA Margin % has ranged from 1.06 to 2.56. According to the industry distribution chart, Vital KSK Holdings ranks #83 out of 119 companies in the Medical Distribution industry, placing it in the top 69.7%.
Is Vital KSK Holdings' EBITDA Margin % too high?
Vital KSK Holdings' current EBITDA Margin % of 4.38% is 122% above median its 10-year median of 1.97. Over the past 10 years, this metric has ranged from a low of 1.06 to a high of 2.56. The Medical Distribution industry median EBITDA Margin % is 4.31. Vital KSK Holdings' value of 4.38% is 1.6% above this industry median. Based on the distribution chart, Vital KSK Holdings ranks #83 out of 119 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Vital KSK Holdings has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vital KSK Holdings' EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Vital KSK Holdings ranks #83 out of 119 companies for EBITDA Margin %. This places Vital KSK Holdings in the lower half of its industry. The industry median EBITDA Margin % is 4.31. Vital KSK Holdings' value of 4.38% is 1.6% above this benchmark. Historically, Vital KSK Holdings' own EBITDA Margin % has ranged from 1.06 to 2.56 over the past decade. While the company's 10-year median is 1.97 vs. the industry median of 4.31, Vital KSK Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vital KSK Holdings's current EBITDA Margin % of 4.38% is 1.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vital KSK Holdings and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vital KSK Holdings's current EBITDA Margin % is 4.38%, which is 122% above median its own 10-year median of 1.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vital KSK Holdings stock overvalued right now?
Based on GuruFocus' analysis, Vital KSK Holdings (TSE:3151) is currently considered Modestly Overvalued. The stock's GF Value™ is 円1,322.65, compared to a current price of 円1,520.00 — trading 14.9% above its estimated fair value. The current EBITDA Margin % is 4.38%, which is 122% above median its 10-year median of 1.97 and 1.6% above the Medical Distribution industry median of 4.31. Vital KSK Holdings' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vital KSK Holdings (TSE:3151), the current EBITDA Margin % is 4.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vital KSK Holdings (TSE:3151) Overvalued in 2026?
Based on GuruFocus' analysis, Vital KSK Holdings stock appears to be overvalued.
The current stock price of 円1,520.00 is trading 14.9% above its estimated GF Value™ of 円1,322.65.
GuruFocus considers Vital KSK Holdings to be Modestly Overvalued.
Key valuation signals for TSE:3151:
EBITDA Margin %: 4.38% (122% above median its 10-year median of 1.97)
GF Value™: 円1,322.65 vs. price of 円1,520.00 (14.9% above fair value)
Industry Position: 1.6% above the Medical Distribution median (#83 of 119)
No single metric tells the full story. See the TSE:3151 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vital KSK Holdings Inc engaged in the wholesale and retail of pharmaceutical products. It operates through the Pharmaceutical Wholesale and Other segments. The Pharmaceutical Wholesale segment sells medicines, diagnostics, and medical devices to hospitals, medical institutions, and health practitioners. The Other segment includes retail of pharmaceutical products, wholesale of agrochemical and veterinary drugs, transportation, nursing care services, and medical consultancies. All the business activity of the group is primarily functioned through Japan and distributes its product within the Korean and to overseas market.
68GF Score
Get the complete analysis for TSE:3151
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3151 has been successfully added to your 
